Viatris Inc. announced the publication of positive Phase 2b CARE study results for cenerimod in Lancet Rheumatology. The study evaluated the efficacy and safety of cenerimod in adults with moderate-to-severe systemic lupus erythematosus (SLE).
Results showed that cenerimod 4 mg demonstrated clinically meaningful and sustained improvement from baseline on multiple measures of SLE disease activity compared to placebo, in addition to stable background SLE therapy. The drug was also found to be well tolerated, with an adverse event profile consistent with its mechanism of action.
Further analysis of the CARE study's SLE-related biomarker data was published in the Annals of the Rheumatic Diseases, providing additional characterization of cenerimod's mechanism of action in patients with SLE. This data was instrumental in informing the design and dose selection for the ongoing Phase 3 OPUS program.
The publication of these results in prominent journals underscores the urgent need for novel agents like cenerimod for the treatment of SLE. This advancement strengthens Viatris's innovative pipeline and its commitment to addressing significant unmet medical needs.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.